We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Depressing Stress Signaling Increases Immune Activity

By LabMedica International staff writers
Posted on 12 Sep 2017
Image: A ribbon model of the beta-2 adrenergic receptor (Photo courtesy of Wikimedia Commons).
Image: A ribbon model of the beta-2 adrenergic receptor (Photo courtesy of Wikimedia Commons).
Cancer researchers evaluating the immune status of the tumor microenvironment found that CD8+ T-cell frequency and functional orientation were regulated by beta-2-adrenergic receptor (beta-AR) signaling and suggested using clinically available beta-blockers in patients to improve responses to immunotherapy.

Anticancer therapies designed to block “checkpoints” within the immune system do not work for all patients, and their efficacy in controlling tumors is often short-lived. To better understand these phenomena and to improve the performance of check point inhibitors, investigators at Roswell Park Cancer Institute (Buffalo, NY, USA) used three strategies: physiologic (manipulation of ambient thermal environment), pharmacologic (beta-blockers), and genetic (beta-2-adrenergic receptor knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models.

They reported in the August 17, 2017, online edition of the journal Cancer Research that reducing beta-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment. This immunologically enriched microenvironment displayed increased frequency of CD8+ T-cells with an effector phenotype and decreased expression of PD-1, in addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio. Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade.

In short, manipulating beta-adrenergic receptor signaling to regulate the immune status of the tumor microenvironment supported the strategic use of clinically available beta-blockers in patients to improve responses to immunotherapy.

“Our bodies respond to certain types of stress - such as fear and anxiety, heat, cold, pain, depression, and even attack by cancer cells - in the same way. We jump into "fight or flight" mode, and the sympathetic nervous system dials up the release of norepinephrine,” said senior author Dr. Elizabeth Repasky, professor of immunology at Roswell Park Cancer Institute. “For reasons that we do not entirely understand yet, prolonged exposure to these stressors often makes our immune cells much less effective. But we demonstrate here that beta blockers, by reducing adrenergic signaling, allow anti-tumor immune cells to become much stronger, and give immunotherapies, and in particular checkpoint inhibitors, a much better chance to work.”

Related Links:
Roswell Park Cancer Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®

Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more